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Background: Peripheral intravenous catheters are among
the most widely used medical devices in the world.
European patients are increasingly aware of the risk of
health care associated infections and the role catheters
play in their facilitation.
Aims: We intend to show that European health care
providers are increasingly aware of the occupational risks
of bloodborne infections such as HIV and hepatitis which
can be transmitted by the needles from catheters and that
the political will is building to take action to ensure safer
devices are provided.
Methods: We review the wide variety of peripheral in-
travenous catheters which are specially engineered to
reduce these risks.
Results: Available safety devices include spring-loaded
retractable needles, guards that shield the dangerous tips
and closed, needle-free access valves for intravenous sets.
Conlusions: It is no longer necessary for patients and
professionals to take risks to health and life when solutions
which minimize these risks are at hand.
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THE intravenous catheter (IVC) is one of the mostubiquitous medical devices in the world.
Approximately four out of five hospitalised pa-
tients have an IVC inserted at some point during
their stay (1). We have already described the
history of this remarkable device (2) and have
provided guidelines as to best practice regarding
its use in the individual patient (3). In this paper we
propose exploring the variety of peripheral IVC
devices and their distribution in Europe, a region
that has long played a leadership role in introdu-
cing medical innovations to the world.
History
The concept of the IVC is seductively simple. The
original ‘Rochester needle’, the brainchild of Dr
David Massa, an anaesthetist at the Mayo Clinic (4,
5), was merely a larger needle slipped over a
smaller one. The larger needle penetrated the
vessel, making room for the smaller one to be slid
in. The latter was soon replaced with a plastic
catheter because polyvinyl chloride was obviously
less traumatic to vessels. It was soon discovered
that the plastic element could fit over the outside of
the needle and still slip effortlessly into the vein.
These landmark inventions occurred over a re-
markably short period of time in the 1950s and
are credited to clinicians at Mayo as well as
scientists working at the medical companies
Deseret (Sandy, UT) and BD (Franklin Lakes, NJ).
Since then, the variety of IVCs and their applica-
tions have expanded at a dizzying pace (Fig. 1).
Today, there are peripheral IVCs (o2 cm, inserted
into veins of the upper extremities), central IVCs
(usually longer than 10 cm, inserted into large veins
which arise proximal to the axilla and empty into
the central circulation) and peripherally inserted
central catheters (usually longer than 20 cm, in-
serted into large arm or groin veins and then
threaded into the central venous circulation).
Devices used for arterial cannulation, dialysis fistula
insertion and implanted chamber access also use the
same basic template as the peripheral IVC.
Some peripheral IVCs have a secondary port
near the insertion site for drawing blood or giving
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injections. These are called ‘ported’ IVCs and are
particularly popular in northern European coun-
tries. IVCs without these ports are called ‘straight’
IVCs. Manufacturing data show that such
cannulae are commonly used in southern Europe
and in the USA. Some peripheral IVCs are fitted
with mechanisms that protect against accidental
needlestick injury (NSI). These are called ‘safety’
catheters. Other peripheral IVCs come with built-in
extension tubing and are called ‘integrated’ devices.
Some have valves that allow access with needleless
devices but prevent blood leakage or pathogen
entry. These are called ‘closed’ systems. There are
also IVCs with combinations of these features; for
example, a safety, integrated, closed catheter (6) has
recently been introduced to the market.
Risks and solutions
Despite the engineering feats that have driven the
evolution of IVC, there are still risks to their use
that are not altogether different from those faced in
the 1950s by Massa (4) and colleagues. In order to
penetrate veins, an IVC must use a sharp needle,
which raises the risk of NSIs. Given the human
immunodeficiency virus (HIV) epidemic and the
prevalence of hepatitis sub-types transmitted par-
enterally, every NSI in the health care setting risks
transmitting a deadly pathogen. A surprising num-
ber of NSIs occur after use, during the disposal
process, and the victims are often not the user but a
downstream person such as the cleaning staff.
Even patients can be victims. Often, NSIs are not
reported, especially when there is a fear of reper-
cussions such as job loss or sanction (7).
In 2000, President Clinton signed into law a
bill requiring the use of safety sharps devices
in health care settings in the USA (8). In 2006,
a similar legislation was passed in Spain (9) and
a directive was issued in Germany (10). Today, a
variety of manufacturers provide safety IVCs for
the European market.
IVCs reside, usually for days on end, in close
proximity to the vein walls. The IVCs invariably
irritate endothelial cells lining the vein walls by
rubbing up against them and/or by exposing
them to the variable pH and osmolarity of the
substances infused through them. Furthermore,
these ‘foreign objects’ serve as magnets for platelets
and fibrinogen, which produce a biofilm that can
promote thrombosis, embolism and bacterial
growth. Redness, pain at the insertion site, blocked
or slow-flowing catheters and phlebitis are among
the everyday consequences of the cohabitation of
catheters with veins. At times the risk can become
life-threatening with bacteraemia, candidaemia or
fungaemia resulting from an infected catheter. To-
day, the polyvinyl chloride of Massa’s day has been
replaced by materials such as Vialont (BD, NJ,
USA) and Ocrilont (Smiths Medical MD, Inc., St
Paul, MN, USA) (forms of polyurethane), which are
significantly less thrombogenic and decrease the
risk of phlebitis and other infectious complications
(11–15).
Experienced inserters usually bring a supply of
gauze to the bedside because intravenous insertion
has traditionally been associated with blood leak-
age. Conventional peripheral catheters confirm
vein entry by the presence of blood flowing into a
‘flashback chamber’, but in most of these devices
the blood does not stop there. It continues along the
Fig. 1. Peripheral intravenous evolution: Tiered
pyramid with product category and their features
(right) and benefits (left). Both ported and straight
peripheral intravenous catheters have evolved to
include safety features which protect the health care
worker from sharps and blood exposure injury and
patient from many complications associated with
invasive venous access.
IVCs in Europe
799
channel left by the exiting stylet and then drips,
leaks or splashes out of the end of the catheter.
Hence the need for gauze to absorb the blood and
limit exposure for the user or reduce soiling of the
patient or linens. This exposure represents a risk to
the inserter, which can be as significant as an NSI if
blood reaches a break in the skin or a mucous
membrane. A study examining the hands of health
care workers (HCWs) for small wounds and
scratches found that 57% of the hands of nurses
showed small, acute or chronic skin injuries (16).
Only 1/10,000ml of infected plasma is required
for hepatitis B virus (HBV) transmission (17). This
amount is easily exceeded by the volume of blood
that drips from the average catheter or even the
amount that remains in the stylet. Furthermore,
HBV is stable in dried blood for up to 7 days.
Therefore, blood dripped on linen represents a
potential risk to a multitude of people in the health
care setting (17). Recently, an IVC (Venflon Pro
Safetyt, BD) has been developed that reduces the
risk of dripping or splashing, thus reducing the risk
of such exposure and providing protection against
bloodborne pathogens.
Types of IVC in the European market
Standard devices
These IVCs are the base products in the market-
place, with the broadest range in both brand and
quality. A shrinking number of such catheters in
Europe continue to use Teflon as a primary catheter
material. Newer, more vein-friendly materials such
as polyurethane are gradually replacing Teflon.
Vialont, a biomaterial made of polyurethane,
has been proven to increase indwell time (length
of time a device is left implanted in a patient) and
reduce the risk of phlebitis (11–15). Even though
the variation in quality from one device to another
may be substantial, these devices have tended
to become ever more commoditised, to the poten-
tial detriment of patients. Today, procurement
decisions are often made with price as the major
discriminator.
Within the category of standard devices, one also
finds winged vs. non-winged catheters. The wing
was originally a feature used to assist with inser-
tion, but its main utility today appears to be in
helping in the fixation of the catheter to the skin
after insertion. Furthermore, there are neonatal
devices, which are usually shorter and have a
smaller diameter (i.e. increased gauge) and also
come in winged and non-winged varieties. Finally,
there are winged needle sets (e.g. ‘butterflies’),
which are commonly used in infants where scalp
vein access is common.
Safety devices
The first safety device appeared in the European
market in 1990. Such devices protect the user
from sharps injury by retracting the needle,
covering its tip after use or using some other
mechanism. Today, the safety catheter share of the
market varies from country to country but remains
relatively low, despite safety devices having been
proven to reduce the rate of NSIs in HCWs to
nearly zero in some studies (18–19). Conversion
from standard to safety devices is expected to
accelerate as governments increasingly mandate
that health care institutions use safety devices to
limit the risk of disease transmission from NSIs.
The safety directive recently passed in Germany
(10) and legislation now in force in Spain (9) are
expected to accelerate the conversion to safety in
these countries.
Currently, safety devices exist in two forms,
active and passive. Passive devices imply that the
safety mechanism is activated during routine per-
formance of the procedure (i.e. the user does not
need to intervene for the mechanism to deploy),
whereas active implies that a distinct and separate
action is required by the user to deploy the point-
protection mechanism.
‘Bloodless’ safety devices
We draw a distinction between first- and second-
generation safety products (Fig. 1). This is based on
the incorporation, in the latter, of additional design
features to reduce the risk of infectious disease
transmission from blood splashing and dripping
during the insertion and disposal procedures.
Integrated devices
Integrated devices define the next tier of sophisti-
cation (Fig. 1). ‘Integration’ refers to the fixed
addition of extension tubing to a standard device.
As with simple non-integrated devices, this class of
device has evolved to incorporate protection
against accidental blood exposure and to reduce
excess manipulation, and consequently premature
device failure, at the insertion site.
K. W. Strauss et al.
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Closed system, integrated safety devices
New generation integrated devices have evolved
one step further to incorporate closed, needleless
access systems that offer potential patient benefit in
addition to the needlepoint protection or HCW
safety (Fig. 1). A ‘closed’ system may afford better
protection against bacterial exposure than conven-
tional ‘open’ ports and, because blood does not
naturally escape from the catheter hub, these de-
vices further minimise the risk of exposing the
clinician to blood during the insertion procedure.
These devices may reduce the risk to patients of
developing health care-associated infections (HAI).
HAIs are infections that the patient did not have on
entry to the hospital, but that developed within
48 h of entry. HAI-fighting devices hold great
promise of benefit in the era of under-funded
health care systems, exhausted antibiotic arma-
mentaria and the ever-increasing incidence of
serious health care infections such as methacillin-
resistant Staphyloccoccus aureus (MRSA).
One of the concerns about closed, integrated
catheters with their built-in extension tubing
is whether they can deliver adequate flow rates.
In an experiment comparing integrated and con-
ventional catheters and involving six different
configurations [glucose vs. artificial blood, pressure
vs. no pressure, extension vs. no extension (on the
conventional device)], we were able to show that
closed, integrated catheters are able to deliver
clinically appropriate flow rates, in the absence of
pressure, of 61ml/min (SD 1.9) of 5% glucose
solution and 45ml/min (SD 2.0) of artificial blood
(Fig. 2, unpublished data on file, available on
request from BD). These translate into 3.66 and
2.70 l/h, respectively, rates that far exceed the
clinical requirements of all but the most extreme
volume-loss conditions.
Current European market
The peripheral intravenous market in Europe can
be stratified into three broad tiers (Fig. 1). The first
tier is comprised of standard catheter devices and
forms the largest segment of the market. The
second tier is comprised of integrated devices.
The third tier consists of the new generation, closed
system, integrated devices, which protect both
patient and HCW.
Each tier may be further sub-divided into safety
and non-safety variants, while the first tier is
additionally split into ported and non-ported cate-
gories (Fig. 1).
Market forces and future evolution
Growth in the overall peripheral intravenous mar-
ket in Europe, about 5% a year over the near term,
is expected to be driven by an ageing population,
and the resultant increase in numbers of people
susceptible to illness (especially cancer) and hospi-
talisation. The increase in safety devices will be
driven by legislative as well as demographic, dis-
ease and individual factors. Recently, the Commit-
tee on Employment and Social Affairs of the
European Commission submitted to the EU Parlia-
ment a motion for a resolution on protecting EU
workers from NSIs (20). It would require that
4 years after passage, European health care institu-
tions would have to certify that they are using
safety devices wherever there is a risk of sharps
injury (20). This would put Europe in line with
USA on this type of legislation. Today, only Spain
(9) and, to some extent, Germany (10) have binding
USA-type legislation.
As in all developed countries, an ageing
European population will require more hospitali-
sations and the use of more peripheral IVC for
complex treatment regimens. The anticipated
rise in cancer with the need to infuse chemother-
apeutic agents will require catheters that help
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Fig. 2. Flow rate analysis of closed system catheter (Nexiva) vs.
conventional catheter with extension (Venflon Pro).
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prevent infection, infiltration and extravasation.
This demographic factor, along with the rise of
HAIs and ‘super bugs’ like MRSA, will promote
the use of integrated, closed, safety intravenous
systems.
Another factor driving the conversion to such
devices may be increased awareness of individual
cases of HCWs who have been injured or worse
by conventional devices. Recently, a British physi-
cian, Dr Peter E. Jensen, died as a result of
an accidental NSI that occurred 30 years ago (21).
He had contracted HBV in 1976 after taking a
blood sample from a patient. The HBV led to liver
cancer, which was the immediate cause of his
death. Media attention on several high-profile
cases of HIV transmission to HCWs in San Fran-
cisco in the 1990s helped drive the case for a safety
law in the USA. Similar forces are at work in
Europe.
Legal requirements for safety catheters
At this writing, only two countries, USA and
Spain, have laws mandating the use of safety
medical devices in both public and private
health care settings. In many ways, the Spanish
law is more precise and proscriptive than the
USA law. In Annex II of the Spanish law (9),
specific requirements are laid out, which a
product must meet before it can be classified as
a ‘safety medical device’ (Table 1). Among others,
these include irreversibility of the activation
mechanism, integration of the mechanism with
the device, inclusion of a tactile, auditory or visual
signal that the device has been activated and a
design that requires minimal change in procedural
technique.
Needs still unmet
Despite all the progress made in preventing NSI,
infection and blood exposure, most new generation
IVCs still do not measure up on one or more of the
following requirements:
Instant blood flashback
The earlier one sees blood flashback after penetra-
tion of the vein, the more likely one is to stop
advancing and the less likely to traverse the oppo-
site wall of the vein (transfixation). In most current
catheters, blood must flow the entire length of the
needle in order to reach the flashback chamber and
alert the user that he/she is in the vein. This delay
means that for a critical instant the inserter is
‘flying blind’ (in the vein but not knowing it) and
risks transfixation. The earliest flashback is cur-
rently provided by notched needles, which reveal
the presence of blood almost the instant the vein
wall is penetrated.
Perfect visibility of puncture site
Infection prevention requires the HCW to observe
the puncture site frequently for bleeding around
the catheter or the inflammatory changes that
signal phlebitis or infection. Clear visibility is
provided by transparent catheter components at
the patient end (e.g. transparent wings) as well as a
transparent dressing. Currently, there is no totally
transparent intravenous system.
Table 1
Requirements for a safety medical device as per Spanish
law (8).
Require-
ment
Issue
addressed
Exact wordings (translated from
Spanish)
1 Purpose of
device
‘The ultimate aim of the safety device
must be the elimination of risk from an
accidental biologic exposure’
2 Ensuring
patient safety
‘The safety device must never
compromise patient safety’
3 Irreversibility
after activation
‘The safety mechanism must activate
irreversibly. The device must not be
able to be deactivated. It must
maintain its protective function until
disposed off’
4 Timely
activation
‘The activation of the safety
mechanism on the device should
coincide with the completion of the
clinical procedure for which it was
used; for example, as soon as the
needle has been withdrawn from the
puncture site’
5 Integrated
safety
‘The safety mechanism should be
integrated into the device, and not be
merely an accessory to it’
6 One-hand
activation
‘Activation of the safety mechanism
should be possible with one hand, in
situations where this is necessary’
7 Activation
signal
‘Activation of the safety mechanism
should be signaled to the user by
auditory, tactile or visual means’
8 Ease of use ‘The safety device should be easy to
use and require little change in
technique on the part of the user’
9 Reliability and
fitness for use
‘The safety device must be reliable
and efficient in accomplishing the
purpose for which it was designed’
K. W. Strauss et al.
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Minimal pain to patient
Intravenous canulation is a painful procedure with
all current catheters. This pain can be reduced by
changes in the sharpness and geometry of the
needle tip, by reducing the gauge of the catheter,
by the use of certain plastics and, most importantly,
by the skill of the inserter. The goal of painless
intravenous insertion is currently an elusive holy
grail for manufacturers.
Minimal infection
Infection risk is multifactorial, depending on the
catheter material, the agent and procedure used to
prepare the skin, the post-insertion site care and the
sterility of infusions given. Currently, IVCs account
for approximately 10% of nosocomial infections in
the hospital (22), and 2.7–3.7 per 1000 central IVCs
and 0.2–0.5 per 1000 peripheral IVCs become in-
fected. In average-sized hospitals (500 beds) using
60,000 peripheral IVCs per year one would expect
up to 30 bloodstream infections in a year due to the
peripheral IVC itself (22).
Minimal thrombotic risk
This depends on many of the same factors as
the infection risk. There are some innovative
approaches to detect and prevent the build-up
of biofilm, but none of these are in commercial
use.
Dynamic softening of the catheter in the vein
Friction of the catheter tip and body against the
endothelium is one of the key pathogenic mechan-
isms in phlebitis. Some catheter materials change
their stiffness after a length of time at body tem-
perature (i.e. inside the vein). Such catheters are
less likely to cause mechanical phlebitis or to kink
and obstruct; consequently, they may also have a
lower infection and thrombotic risk (11–15). How-
ever, it is more difficult to draw blood back through
such a catheter (not a recommended procedure due
to the high potential for creating haemolysis, but,
unfortunately, one often performed).
Total elimination of blood exposure to the user
An IVC, which was totally closed would prevent
the escape of blood into the environment, provide
protection against mucocutaneous exposure to
blood of the user and eliminate the risk of micro-
organism entry into the patient. Unfortunately,
catheter systems are made to provide intermittent
access of drugs and other fluids to the patient, and
this, by definition, requires opening and closing of
the system. Permanently closed systems are diffi-
cult to conceive of at the moment.
Multi-lumen port access
Such catheters, when used peripherally, provide
many of the advantages of a central venous cathe-
ter. Multiple ports can be provided by including an
additional port on the catheter itself (the ‘ported’
catheters used frequently in Europe), by the attach-
ment of a stop cock or by the use of extension
tubing (either attached or integral to the catheter)
with multiple ports. Unfortunately, the higher the
number of ports, the higher the risk of blood escape
or microbial entry.
Needleless access to ports
Such catheter systems are more ‘closed’ to bacterial
entry than conventional ones and reduce needle-
stick risk.
Simple to dress, difficult to snag
The optimal catheter would have a completely
flat profile allowing the dressing to cover it
smoothly without wrinkling or binding. Such a
covering would be less likely to catch on objects
in the environment or to come loose between
dressings and would reduce the friction of the
external catheter body on the patient’s skin to a
minimum.
Conclusion
The European peripheral intravenous market is
currently being served with a range, which varies
from low-end conventional to high-end integrated,
closed safety devices (Fig. 1). As one mounts this
pyramid, the costs inevitably increase but so do
safety and clinical values for both users and
patients. Several forces are driving the market ‘up
the pyramid’, including legislative, clinical and
media factors. More study is needed to determine
the degree to which the benefits to both user and
patient compensate for the additional cost and
training that these new devices entail. Manufac-
turers should not assume that the summit has
been reached with their latest offerings, but should
focus on the still-unmet needs in designing future
solutions.
IVCs in Europe
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